Novo Nordisk CEO apparent sees even more focus on diabetes

March 17, 2015 4:00 PM

2 0

LONDON (Reuters) - Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss.

Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60-year-old Lars Sorensen, said diabetes was likely to account for 80-90 percent of sales in 10 years, up from 79 percent now.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page